Results 71 to 80 of about 2,162 (171)

Remimazolam for procedural sedation in gastrointestinal endoscopy: real-life, single center observational study

BMC Gastroenterology
Background and aim Remimazolam has proved to be a very promising sedative drug in randomized clinical trials for usage in a wide spectrum of patients, including critically ill ones.
Conigliaro Rita, Pigò Flavia, Caiazzo Anna, Grande Giuseppe, Russo Salvatore, Cocca Silvia, Lupo Marinella, Marocchi Margherita, Marsico Maria, Sculli Simone, Bertani Helga   +10 more
doaj   +1 more source

Evaluating Remimazolam for Procedural Sedation

Current Neuropharmacology
Remimazolam, a novel short-acting benzodiazepine, has garnered interest in the realm of procedural sedation. Targeting a desired level of sedation requires a medication with both anesthetic and analgesic properties, particularly in non-operating room anesthetizing locations.
Monanian, Genevieve, Yonel, Brandon, Rupert, Deborah, Razak, Alina, DeLemos, Michelle, Bergese, Sergio D.   +5 more
openaire   +2 more sources

The 90% effective dose (ED90) of remimazolam for inhibiting responses to the insertion of a duodenoscope during ERCP

BMC Anesthesiology
Background Compared to midazolam, remimazolam has a faster onset and offset of hypnotic effect, as well as cardiorespiratory stability, this study aims to determine the 90% effective dose (ED90) of remimazolam to inhibit responses to insertion of a ...
Yan Guo, Shu-An Dong, Jia Shi, Hui-Rong Chen, Sha-Sha Liu, Li-Li Wu, Jing-Hua Wang, Li Zhang, Huan-Xi Li, Jian-Bo Yu   +9 more
doaj   +1 more source

A randomized controlled study of remimazolam in preschool children undergoing adenotonsillectomy

Frontiers in Pharmacology
BackgroundAt present, remimazolam is widely used for general anesthesia. However, the literature on the usability of remimazolam is limited in preschool children.
Yong Wu, Fenjun Wang, Kai Zhu, Li Ling, Wangping Zhang   +4 more
doaj   +1 more source

Remimazolam Besylate

American Journal of Health-System Pharmacy, 2021
openaire   +2 more sources

Comparison of efficacy and safety of equivalent doses of remimazolam versus propofol for gastroscopy anesthesia in elderly patients

Scientific Reports
Remimazolam, a novel intravenous anesthetic, has been proven to be safe and efficacious in the gastroscopy setting among the elderly. However, reports comparing the effectiveness and safety of using equivalent doses of remimazolam with propofol have not ...
Di Chen, Min Liao, Xiao-ru Wu, Tang-yuan-meng Zhao, Hu Sun   +4 more
doaj   +1 more source

Safety and effcacy of remimazolam tosilate for sedation during combined spinal-epidural anesthesia for orthopedic procedures: a randomized controlled trial

BMC Anesthesiology
Objective The objective of this study was to assess the efficacy and safety of Remimazolam in the context of combined spinal-epidural anesthesia for sedation during orthopedic surgery.
Yufei Chen, Yimeng Cai, Guoqing Yu, Xi Zhang, Tian Hu, Rui Xue   +5 more
doaj   +1 more source

Transcriptomic analysis and experiments revealed that remimazolam promotes proliferation and G1/S transition in HCT8 cells

Frontiers in Oncology
BackgroundRemimazolam is a new ultrashort-acting benzodiazepine for sedation and anesthesia. The effects of remimazolam and the mechanism by which it functions in cancer cells have not been determined.
Runjia Wang, Shuai Li, Han Hu, Qi Hou, Huaqing Chu, Yu Hou, Cheng Ni, Yuliang Ran, Hui Zheng   +8 more
doaj   +1 more source

Safety of Remimazolam in Vulnerable Populations

Drug Design, Development and Therapy
Vulnerable populations require careful consideration in drug selection due to their unique physiological conditions. Remimazolam, an innovative ultra-short-acting benzodiazepine, presents several advantages, including rapid onset, brief duration of action, and high predictability.
Jia-Yi Ge, Bo-Ran Deng, Xiao-Hua Cao, Xing-Jun Liu   +3 more
openaire   +4 more sources

Clinical Pharmacokinetics and Pharmacodynamics of Remimazolam

Clinical Pharmacokinetics
Remimazolam is a benzodiazepine with a high affinity for the γ-aminobutyric acid type A-receptor thereby inducing sedation and amnesia. It is a short-acting drug, has a fast onset, short duration of action, and a predictable recovery profile. Remimazolam is metabolized mainly into CNS7054.
Bas T. de Jong, Douglas J. Eleveld, Keira P. Mason, Michel M. R. F. Struys   +3 more
openaire   +2 more sources